

Anika Therapeutics, Inc.
 Form 4
 March 02, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 LAND RAYMOND J

(Last) (First) (Middle)
 32 WIGGINS AVENUE
 (Street)
 BEDFORD, MA 01730
 (City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 Anika Therapeutics, Inc. [ANIK]

3. Date of Earliest Transaction
 (Month/Day/Year)
 02/26/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount (A) or (D) Price		
Common Stock ⁽¹⁾	02/26/2015		M		4,500 A \$ 10.5	19,689	D
Common Stock ⁽²⁾	02/26/2015		M		1,770 A \$ 10.51	21,459	D
Common Stock	02/26/2015		F		1,649 ⁽³⁾ D \$ 39.96	19,810	D
Common Stock	02/27/2015		S		4,621 D \$ 39.49	15,189	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474 (9-02)

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Stock Appreciation Right	\$ 10.5	02/26/2015		A	4,500	<u>(1)</u> 01/24/2016	Common Stock	4,500
Stock Appreciation Right	\$ 10.51	02/26/2015		A	1,770	<u>(2)</u> 01/26/2016	Common Stock	1,770

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LAND RAYMOND J 32 WIGGINS AVENUE BEDFORD, MA 01730		X		

Signatures

/s/ Sylvia Cheung for Charles H. Sherwood,
Attorney-in-Fact 03/02/2015

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercise of stock appreciation rights ("SARs") granted on January 24, 2006 vesting in four annual installments beginning January 24, 2007.
- (2) Exercise of SARs granted on January 26, 2006 vesting in four annual installments beginning January 26, 2007.
- (3) Reflects 1,649 shares of common stock to cover the exercise of the above listed SARs awards by the Reporting Person on February 26, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Edgar Filing: Anika Therapeutics, Inc. - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.